drugs
No evidence to justify price increases for eight of top 10 most costly drugs
ICER’s latest Unsupported Price Increase report from the Institute for Clinical and Economic Review finds that, last year, eight of the ten most costly drugs in the US that raised net prices well over the rate of general inflation, had no new clinical evidence of effectiveness to justify the increases. The increases on just these…
Read MoreAnalysis: Medicare is Negotiating Drug Prices — Why it Matters
This is historic. Pharma has been fighting Medicare drug price negotiation for decades because it’s the start of reining in their extreme prices. But it’s just a start. Don’t start spending your savings yet. Read more
Read MoreICER seeking nominations for New England evidence review council
The Institute for Economic and Clinical Review (ICER) is seeking nominations for new members to the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). In my time on the New England CEPAC, it was an exciting dive into learning new things with a team of exceptional experts and colleagues from across the region.…
Read MoreICER fair access report finds improvements but problems with transparency
ICER’s third annual Barriers to Fair Access report found that most prescription drug coverage policies met fair rules for patient access. This is an improvement over previous years suggesting that transparency and public sunlight works. But the report also found that policies needed more transparency and are too complex. Policies on which patients are eligible…
Read MoreCT Healthcare Explained — what’s next?
Hopefully, you’ve found our short Sunday Health Policy Minute emails informative and helpful. This is just the beginning of CT Healthcare Explained’s efforts to help make sense of our state’s unreasonably complex system. Hopefully, you’ve accessed the site resources including explainer videos, Basics, and Deeper Dives on the current seventeen topics. Consumers, policymakers, clinicians, students,…
Read MorePlans for CT opioid settlement far better than our tobacco history
Connecticut is using our $300 million settlement from opioid lawsuits far better than we did with the 1998 tobacco settlement and similarly to our surrounding states, according to a cross-state analysis of opioid settlement details from Vital Strategies. The report gives details on the uses of the funds, who decides, public reporting requirements, and a…
Read MoreSummer reading — Rough Sleepers
I thought I understood healthcare for the homeless, but I had a lot to learn. Rough Sleepers: Dr. Jim O’Connell’s Urgent Mission to Bring Healing to Homeless People describes Boston’s Healthcare for the Homeless Program by following Dr. Jim O’Connell’s career of caring for people who live, and sleep, on the streets. He ended up…
Read MoreAnalysis: Connecticut is doing something about healthcare costs, finally
I’ve long been a critic of our state’s inaction on controlling healthcare costs, but I may have to eat my words. On Wednesday, Connecticut policymakers took a big step toward controlling the two biggest drivers of rising healthcare costs – hospital and prescription drug prices. Read more
Read MoreState Health Compare finds CT access to care is good but costly
Connecticut residents have very good access to healthcare, but care is unaffordable for too many. 93% of CT residents have a usual source of care According to updated health metrics, in 2020-2021, Connecticut ranked third best among states in the percent of residents with a usual source of care. Having a usual source of care…
Read MoreOp-Ed: This Is Why CT Can’t Lower Healthcare Costs
After years of deliberation, Connecticut’s state plan to cap healthcare costs has finally identified the drivers of those costs in our state. But the Steering Committee, dominated by healthcare industries, still isn’t brave enough hold the overspenders accountable. They want the profitable industries to come up with ideas to lower their own costs (what could…
Read More